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RESUMO: Introdução: Neste caso, descrevemos a apresentação 
rara da metástase orbitária de um carcinoma renal de células 
claras. Apresentação do caso: Apresentamos um caso de um 
homem de 57 anos de idade, que subitamente perdeu a visão em 
seu olho esquerdo associada à paralisia da abdução do mesmo. A 
ressonância magnética do crânio revelou um tumor intra-orbitário 
esquerdo com dimensões de 21,8 x 19,6 mm, provocando um 
deslocamento centro-lateral com consequente compressão do 
nervo óptico e do músculo reto lateral homolateral. O paciente foi 
submetido à remoção cirúrgica da lesão. O diagnóstico histológico 
indicou metástase de carcinoma renal de células claras confirmada 
pela tomografia computadorizada abdominal (TC), que apresentou 
neoplasia no terço superior do rim esquerdo, medindo 3,5 x 3,4 
cm com reforço heterogêneo após administração intravenosa de 
contraste. Conclusão: Este caso descreveu a apresentação rara 
de uma metástase orbital de carcinoma renal de células claras. 
A apresentação inicial do paciente foi amarose fugaz e paralisia 
homolateral do nervo abducente. A metástase orbital de carcinoma 
renal de células claras é rara, no entanto, o exame histológico 
conclui o diagnóstico.
Descritores: Carcinoma de células renais; Neoplasias renais/
diagnóstico por imagem; Amaurose fugaz; Neoplasias orbitárias; 
Doenças do nervo abducente.
ABSTRACT: Background: In this case we describe the rare 
presentation of orbital metastasis of a clear cell renal carcinoma. 
Case Report: We present a case of a 57-year-old male with 
suddenly lost the vision in his left eye and homolateral abducens 
palsy. The magnetic resonance imaging of the skull revealed a 
left intraorbital tumor with center-lateral displacement measuring 
21.8 x 19.6 mm, compressing the optic nerve and the homolateral 
lateral rectus muscle. The patient underwent surgical removal 
of the lesion. The histologic diagnosis indicated clear cell renal 
carcinoma metastasis confirmed by the abdominal computed 
tomography (CT), which showed a neoplasia in the upper third 
of the left kidney measuring 3.5 x 3.4 cm with heterogeneous 
reinforcement after intravenous contrast administration. 
Conclusion: This case described the rare presentation of a clear 
cell renal carcinoma metastasis in orbit. The initial presentation 
of patient was amarosis fugax and homolateral abducens palsy. 
Orbital metastasis of clear cell renal carcinoma are rare, however, 
the histologic exam conclude the diagnosis. 
Keywords: Carcinoma, renal cell; Kidney neoplasms/diagnostic 
imaging; Orbital neoplasms; Amaurosis fugax; Abducens nerve 
diseases.
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INTRODUCTION
Renal cell carcinoma (RCC) accounts for 3% of all cancers in adult patients and it is twice as 
frequent in males. Clear cell renal carcinoma (CCRC) is 
most prevalent variant of this neoplasia, responsible for 70 
to 75% of all cases1. As the most frequent metastasis are 
breast (48%), prostate (12%), skin (12%) and lungs (8%)2. 
Orbital metastasis are rare and represents less than 2% of 
all ophtalmics metastasis. We report the case of a patient 
with renal cell carcinoma who presented the symptoms of 
orbital metastasis as the initial manifestation of the disease.
CASE REPORT
Male, 57 years old, without comorbidities (systemic 
arterial hypertension, diabetes mellitus), who did not take 
any medication for chronic conditions, and ex-smoker, 
attended the Neurosurgery Department at the Santa Casa 
de Misericórdia de Sobral Hospital. This patient reported 
that six months ago suddenly lost the vision in his left eye 
and that it had been deviated medially (Figure 1), with no 
other associated symptoms. 
Figure 1. Patient with esotropia of the left eye due to involvement 
of the ipsilateral lateral rectus muscle
Upon admission, the patient’s only complaint was 
of amaurosis of the left eye. He denied other symptoms: 
hematuria, dysuria, or back pain. Physical examination 
showed no visceromegaly or abdominal mass. The 
magnetic resonance imaging of the skull revealed a 
left intraorbital tumor with center-lateral displacement 
measuring 21.8 x 19.6 mm, compressing the optic nerve 
and the homolateral lateral rectus muscle (Figure 2). From 
the results of the exam, surgical removal of the orbital 
tumor was indicated (12/02/2016). The histopathological 
report was compatible with CCRCC and confirmed with 
immunohistochemistry (Table 1). 
Figure 2. T1-weighted magnetic resonance imaging showing 
metastatic tumor from renal cell carcinoma in the left orbit. 
Center-lateral displacement compressing the optic nerve and the 
lateral rectus muscle. Dimensions: 21.8 x 19.6 mm
Table 1: Left-orbit immunohistochemistry report
Accompanying Files
Antibody Clone Interpretation
RCC PN15 Positive
EMA E29 Positive
CK7 OV-TL-12/30 Negative
TTF-1 8G7/1 Negative
VIMENTINA V9 Negative
CD10 56C6 Negative
PAX8 MRQ-50 Negative
CK20 K20.8 Negative
The clinical investigation of the patient 
proceeded with the request of an abdominal computed 
tomography (CT), which showed (neoplasia in the upper 
third of the left kidney measuring 3.5 x 3.4 cm with 
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heterogeneous reinforcement after intravenous contrast 
administration(white arrow) (Figure 3) and a chest CT 
(nodular image with homogeneous reinforcement after the 
use of intravenous contrast in the anterior segment of the 
upper lobe of the left lung. Suggestive of metastatic nodule, 
associated with left perihilar lymph node enlargement). 
According to findings from the complementary exams, 
partial nephrectomy surgery for tumor resection in the left 
kidney was indicated (30/08/2016). 
Figure 3. Axial section of computed tomography of abdomen 
revealed tumor mass in the left kidney measuring 3.5 x 3.4 cm
Figure 4. A: Histopathology of the tissue removed during partial 
nephrectomy of the left kidney Renal parenchyma hosting 
neoplasia of epithelial origin composed of atypical cells, irregular 
nuclei and macronuclei, with abundant clear cytoplasm in tubular 
and cordonal arrangements suggestive of Clear Cell Renal 
Carcinoma. B: Some healthy glomerular regions interspersed 
with others affected by neoplasia can be seen. H&E staining x20
Surgery occurred adequately, without complications, 
and the patient was discharged after 4 days. Histopathology 
of the tissue removed during nephrectomy revealed 
renal parenchyma, hosting a neoplasia of epithelial 
origin composed of atypical cells, irregular nuclei and 
macronuclei, with abundant clear cytoplasm in tubular and 
cordonal arrangements suggestive of CCRC (Figure 4).
DISCUSSION
Although the case reported belonged to the 
epidemiological group most commonly affected by RCC 
(male and in the 5th and 6th decade of life), it is worth 
highlighting due to its unusual clinical presentation and 
atypical evolution of ocular symptoms. Classically, the 
most characteristic symptoms of metastatic orbital RCC 
are: proptosis, ptosis, and pain, all of which are absent in 
this report. Another unusual feature present in this case was 
the sudden onset of symptoms, amaurosis fugax in the left 
eye and ipsilateral esotropia due to involvement of the optic 
nerve and lateral rectus muscle, respectively. 
RCC treatment depends on the evolution stage of 
the disease, and it presents options for clinical and surgical 
treatments. Molecular-targeted therapies are currently 
the clinical treatment of choice. They are more effective 
against RCC than chemotherapy, with response rates of 
approximately 40 and 10%, respectively. There are several 
ongoing studies investigating new drugs for the systemic 
treatment of RCC3.
Until recently, complete RCC resection was gold 
standard therapy in cases with strictly localized disease. 
However, it is now known that in smaller tumors it is 
possible to proceed with less aggressive approaches. In 
tumors of up to 4 centimeters, partial nephrectomy is 
chosen because there is no significant difference in survival, 
and long-term recurrent disease in detriment of radical 
nephrectomy4.
Surgical treatment also plays an important role in 
patients who already have distant metastasis. One study 
compared isolated immunotherapy versus nephrectomy 
plus immunotherapy in patients with metastatic RCC. The 
results showed greater long-term survival in the group 
of patients submitted to therapy combined with surgical 
approach4.
CONCLUSION
In this case report, even though the patient presented 
metastasis to lung and orbit after partial nephrectomy, he 
evolved with good postoperative recovery in a one-month 
segment; and the patient was referred to a reference center 
for oncology for post-surgical follow-up.
Acknowledgments: No funding was used in the production of this article. 
Author disclosure statement: None of the contributing authors have any conflict of interest, including specific financial interests or 
361
Cavalcante-Filho JRM, et al. Orbital metastasis of clear cell renal carcinoma.
relationships and affiliations relevant to the subject matter or materials discussed in the article. No competing financial interests exist.
Participação dos autores na elaboração do Relato de Caso: José Renan Miranda Cavalcante Filho e Karlos Jennysson Sousa Soares 
- Coleta de dados; José Renan Miranda Cavalcante Filho, Rafael Paiva Arruda, Elson Arruda Linhares, Paulo Roberto Lacerda Leal, 
Irismar de Azevedo Andrade e Karlos Jennysson Sousa Soares - Revisão de literatura; José Renan Miranda Cavalcante Filho, Rafael 
Paiva Arruda, Paulo Roberto Lacerda Leal e Karlos Jennysson Sousa Soares - Escrita do artigo.
REFERENCES
1. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 
WHO classification of renal tumours of the adults. Eur Urol. 
2006;49:798- 805. doi: 10.1016/j.eururo.2005.11.035
2. Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients 
with orbital tumors and simulating lesions. The Montgomery 
Lecture, Part I. Opthalmology. 2004;111:997-1008.4. doi: 
10.1016/j.ophtha.2003.01.002
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, 
Bukowski RM, Oudard S, et al. Overall survival and 
updated results for sunitinib compared with interferon alfa in 
patients with metastatic renal cell carcinoma. J Clin Oncol. 
2009;27:3584. doi: 10.1200/JCO.2008.20.1293
4. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk 
MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC; 
European Association of Urology Guideline Group. EAU 
guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 
2010;58(3):398-406. doi: 10.1016/j.eururo.2010.06.032.
Recebido: 04.06.17
Aceito: 05.08.19
